Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Jan;23(1):86–90. doi: 10.1128/aac.23.1.86

In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

D L Shungu, E Weinberg, H H Gadebusch
PMCID: PMC184622  PMID: 6219622

Abstract

A comparison was made of the in vitro activities of norfloxacin and of nine other orally administered antibacterial agents against 180 clinical isolates representing the bacterial species most frequently implicated in infections of the gastrointestinal tract in humans. The 90% minimal inhibitory concentrations showed norfloxacin to be 4, 15, 4, 17, 17, 17, and 33 times more active than the next best compound tested against Campylobacter fetus subsp. jejuni, Escherichia coli, Salmonella spp., Shigella spp., Vibrio cholerae, Vibrio parahaemolyticus, and Yersinia enterocolitica, respectively, with an overall 90% minimal inhibitory concentration of less than or equal to 0.5 micrograms/ml. Norfloxacin was least active against Clostridium difficile (90% minimal inhibitory concentration, 128 micrograms/ml). These results should encourage further evaluation of norfloxacin as a potential chemotherapeutic agent in the treatment of enteric bacterial infections for which antibiotic therapy is indicated.

Full text

PDF
89

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bachrach S. J. Successful treatment of an institutional outbreak of shigellosis. Clin Pediatr (Phila) 1981 Feb;20(2):127–131. doi: 10.1177/000992288102000207. [DOI] [PubMed] [Google Scholar]
  2. Black R. E., Levine M. M., Clements M. L., Cisneros L., Daya V. Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo. Rev Infect Dis. 1982 Mar-Apr;4(2):540–545. doi: 10.1093/clinids/4.2.540. [DOI] [PubMed] [Google Scholar]
  3. Boppana V. K., Swanson B. N. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother. 1982 May;21(5):808–810. doi: 10.1128/aac.21.5.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burman L. G. Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria. J Antimicrob Chemother. 1977 Sep;3(5):509–516. doi: 10.1093/jac/3.5.509. [DOI] [PubMed] [Google Scholar]
  5. Byers P. A., Dupont H. L., Goldschmidt M. C. Antimicrobial susceptibilities of shigellae isolated in Houston, Texas, in 1974. Antimicrob Agents Chemother. 1976 Feb;9(2):288–291. doi: 10.1128/aac.9.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clark H., Brown N. K., Wallace J. F., Turck M. Emergence of resistant organisms as a function of dose in oxolinic acid therapy. Am J Med Sci. 1971 Mar;261(3):145–148. doi: 10.1097/00000441-197103000-00003. [DOI] [PubMed] [Google Scholar]
  7. Dornbusch K., Gezelius L. Susceptibility testing to trimethoprim alone and combined with sulphonamides. Chemotherapy. 1980;26(6):418–426. doi: 10.1159/000237937. [DOI] [PubMed] [Google Scholar]
  8. Downs J., Andriole V. T., Ryan J. L. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Apr;21(4):670–672. doi: 10.1128/aac.21.4.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. DuPont H. L., Hornick R. B. Clinical approach to infectious diarrheas. Medicine (Baltimore) 1973 Jul;52(4):265–270. [PubMed] [Google Scholar]
  10. Farrar W. E., Jr Antibiotic resistance in intestinal bacteria. Clin Gastroenterol. 1979 Sep;8(3):803–826. [PubMed] [Google Scholar]
  11. Gadebusch H. H., Shungu D. L., Weinberg E., Chung S. K. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents. Infection. 1982 Jan;10(1):41–44. doi: 10.1007/BF01640837. [DOI] [PubMed] [Google Scholar]
  12. Gleckman R., Blagg N., Joubert D. W. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy. 1981 Jul-Aug;1(1):14–20. doi: 10.1002/j.1875-9114.1981.tb03548.x. [DOI] [PubMed] [Google Scholar]
  13. Gordon R. C., Thompson T. R., Carlson W., Dyke J. W., Stevens L. I. Antimicrobial resistance of Shigellae isolated in Michigan. JAMA. 1975 Mar 17;231(11):1159–1161. [PubMed] [Google Scholar]
  14. Haltalin K. C., Nelson J. D., Kusmiesz H. T. Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child. 1973 Apr;48(4):305–312. doi: 10.1136/adc.48.4.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hansson H. B., Walder M., Juhlin I. Susceptibility of shigellae to mecillinam, nalidixic acid, trimethoprim, and five other antimicrobial agents. Antimicrob Agents Chemother. 1981 Feb;19(2):271–273. doi: 10.1128/aac.19.2.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hirai K., Ito A., Abe Y., Suzue S., Irikura T., Inoue M., Mitsuhashi S. Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother. 1981 Jan;19(1):188–189. doi: 10.1128/aac.19.1.188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ito A., Hirai K., Inoue M., Koga H., Suzue S., Irikura T., Mitsuhashi S. In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother. 1980 Feb;17(2):103–108. doi: 10.1128/aac.17.2.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Juhlin I., Winblad S. Susceptibility to mecillinam and other antibiotics of 28 O-serotypes of Yersinia enterocolitica. J Antimicrob Chemother. 1981 Oct;8(4):291–297. doi: 10.1093/jac/8.4.291. [DOI] [PubMed] [Google Scholar]
  19. Khan M. Y., Siddiqui Y., Gruninger R. P. Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1981 Aug;20(2):265–266. doi: 10.1128/aac.20.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. King A., Warren C., Shannon K., Phillips I. In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother. 1982 Apr;21(4):604–607. doi: 10.1128/aac.21.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kronborg I. J., Howard A. Diarrhoea: causes and specific treatment. Drugs. 1981 Jan;21(1):62–68. doi: 10.2165/00003495-198121010-00004. [DOI] [PubMed] [Google Scholar]
  22. Lambert H. P. Antimicrobial agents in diarrhoeal disease. Clin Gastroenterol. 1979 Sep;8(3):827–833. [PubMed] [Google Scholar]
  23. Murray B. E., Rensimer E. R., DuPont H. L. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med. 1982 Jan 21;306(3):130–135. doi: 10.1056/NEJM198201213060302. [DOI] [PubMed] [Google Scholar]
  24. Ribner B. S., Freimer E. H. Oxolinic acid for the treatment of chronic gastrointestinal Shigella carriers. Am J Trop Med Hyg. 1978 Jul;27(4):840–842. doi: 10.4269/ajtmh.1978.27.840. [DOI] [PubMed] [Google Scholar]
  25. Sleijfer D. T., Mulder N. H., de Vries-Hospers H. G., Fidler V., Nieweg H. O., van der Waaij D., van Saene H. K. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer. 1980 Jun;16(6):859–869. doi: 10.1016/0014-2964(80)90140-1. [DOI] [PubMed] [Google Scholar]
  26. Sutter V. L., Barry A. L., Wilkins T. D., Zabransky R. J. Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother. 1979 Oct;16(4):495–502. doi: 10.1128/aac.16.4.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. van der Waaij D., Aberson J., Thijm H. A., Welling G. W. The screening of four aminoglycosides in the selective decontamination of the digestive tract in mice. Infection. 1982 Jan;10(1):35–40. doi: 10.1007/BF01640836. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES